Janus Henderson Group PLC Has $1.04 Billion Stock Position in Boston Scientific Corporation $BSX

Janus Henderson Group PLC raised its stake in Boston Scientific Corporation (NYSE:BSX) by 31.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,497,366 shares of the medical equipment provider’s stock after acquiring an additional 3,907,981 shares during the quarter. Janus Henderson Group PLC’s holdings in Boston Scientific were worth $1,035,202,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. Bangor Savings Bank boosted its stake in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific in the 1st quarter valued at $28,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted EPS of $0.86, above the $0.83 consensus estimate, while revenue of $5.442 billion exceeded expectations of roughly $5.36 billion. Sales increased 7.5% year over year, led by 8.3% growth in Cardiovascular and strong international performance. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: The company completed a $2 billion accelerated share repurchase program and announced a $1.5 billion investment in MiRus, including an option to acquire its transcatheter aortic valve replacement business. These actions could support long-term growth and per-share results. Boston Scientific Q2 revenue rises to $5.442 billion
• Neutral Sentiment: Boston Scientific is beginning a global restructuring program expected to cost $700 million to $800 million through 2029, with anticipated headcount reductions and potential annual cost savings of about $500 million. Near-term charges may weigh on results, while savings could improve margins later. Boston Scientific expects headcount reductions amid restructuring initiative
• Negative Sentiment: The company reduced full-year 2026 adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41, below the approximately $3.36 consensus. Third-quarter EPS and revenue guidance also trail analyst expectations.
• Negative Sentiment: Management cited softer-than-expected Watchman demand, unexpected challenges in the heart-implant market and competition affecting the electrophysiology business. The lower outlook overshadowed the quarterly beat and raised concerns about growth execution. Boston Scientific trims annual profit forecast on softer Watchman device demand
• Negative Sentiment: Analysts responded by cutting price targets, including BTIG to $60 from $65, although it maintained a Buy rating. BTIG lowers Boston Scientific price target

Boston Scientific Price Performance

Shares of NYSE BSX opened at $46.06 on Thursday. The business has a fifty day moving average price of $46.57 and a two-hundred day moving average price of $62.73. The stock has a market capitalization of $68.47 billion, a PE ratio of 19.27, a P/E/G ratio of 0.88 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period in the prior year, the firm posted $0.75 EPS. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.35 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In other news, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 9,800 shares of company stock valued at $554,012 over the last quarter. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Barclays lowered their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Mizuho decreased their price target on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Leerink Partners decreased their price target on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research note on Thursday, May 28th. Robert W. Baird set a $70.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. Finally, Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.